124 related articles for article (PubMed ID: 10713660)
21. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Joint Lung Cancer Study Group.
Helsing M; Bergman B; Thaning L; Hero U
Eur J Cancer; 1998 Jun; 34(7):1036-44. PubMed ID: 9849452
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier Oncology Group Trial.
Faylona EA; Loehrer PJ; Ansari R; Sandler AB; Gonin R; Einhorn LH
J Clin Oncol; 1995 May; 13(5):1209-14. PubMed ID: 7738623
[TBL] [Abstract][Full Text] [Related]
23. Combination chemotherapy using carboplatin (JM-8) and etoposide (JET therapy) for recurrent malignant gliomas: a phase II study.
Watanabe K; Kanaya H; Fujiyama Y; Kim P
Acta Neurochir (Wien); 2002 Dec; 144(12):1265-70; discussion 1270. PubMed ID: 12478337
[TBL] [Abstract][Full Text] [Related]
24. Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC).
Alici S; Saip P; Eralp Y; Aydiner A; Topuz E
Am J Clin Oncol; 2003 Aug; 26(4):358-62. PubMed ID: 12902885
[TBL] [Abstract][Full Text] [Related]
25. A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer.
Planting A; Kho S; van der Burg M; Goey H; Schellens J; van den Bent M; van der Gaast A; de Boer-Dennert M; Stoter G; Verweij J
Cancer Chemother Pharmacol; 1997; 40(4):347-52. PubMed ID: 9225954
[TBL] [Abstract][Full Text] [Related]
26. Vincristine with high-dose etoposide in advanced breast cancer: a phase II trial of the Piedmont Oncology Association.
Thomas GW; Muss HB; Jackson DV; McCulloch J; Ramseur W; McFarland J; Hoen H; Pavy M; Heath R
Cancer Chemother Pharmacol; 1994; 35(2):165-8. PubMed ID: 7987995
[TBL] [Abstract][Full Text] [Related]
27. A phase II study of prolonged oral etoposide in advanced or recurrent carcinoma of the cervix.
Morris M; Brader KR; Burke TW; Levenback CF; Gershenson DM
Gynecol Oncol; 1998 Aug; 70(2):215-8. PubMed ID: 9740693
[TBL] [Abstract][Full Text] [Related]
28. Ten-day schedule oral etoposide therapy in advanced childhood malignancies.
Schiavetti A; Varrasso G; Maurizi P; Cappelli C; Clerico A; Properzi E; Castello MA
J Pediatr Hematol Oncol; 2000; 22(2):119-24. PubMed ID: 10779024
[TBL] [Abstract][Full Text] [Related]
29. Oral etoposide for refractory or recurrent epithelial ovarian cancer.
Thavaramara T; Tangjitgamol S; Manusirivithaya S; Leelahakorn S
J Med Assoc Thai; 2009 Nov; 92(11):1397-405. PubMed ID: 19938729
[TBL] [Abstract][Full Text] [Related]
30. Phase I and pharmacologic study of 7- and 21-day continuous etoposide infusion in patients with advanced cancer.
Robert F; Chen S; Miller AA; Lee BC; Molthrop DC; Wheeler RH
Cancer Chemother Pharmacol; 1996; 38(5):459-65. PubMed ID: 8765440
[TBL] [Abstract][Full Text] [Related]
31. Guidelines for the use of radio-iodine, thyroid hormone, and treatment of metastatic disease in patients with differentiated thyroid cancer.
Paloyan E; Walker RP; Lawrence AM
Surg Oncol Clin N Am; 1998 Oct; 7(4):665-80. PubMed ID: 9735128
[TBL] [Abstract][Full Text] [Related]
32. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.
Souhami RL; Spiro SG; Rudd RM; Ruiz de Elvira MC; James LE; Gower NH; Lamont A; Harper PG
J Natl Cancer Inst; 1997 Apr; 89(8):577-80. PubMed ID: 9106647
[TBL] [Abstract][Full Text] [Related]
33. Oral etoposide for platinum-resistant and recurrent epithelial ovarian cancer: a study by the Anatolian Society of Medical Oncology.
Kucukoner M; Isikdogan A; Yaman S; Gumusay O; Unal O; Ulas A; Elkiran ET; Kaplan MA; Ozdemir N; Inal A; Urakci Z; Buyukberber S
Asian Pac J Cancer Prev; 2012; 13(8):3973-6. PubMed ID: 23098502
[TBL] [Abstract][Full Text] [Related]
34. Combination chemotherapy with cisplatin, carboplatin, and etoposide in advanced malignancy: a phase I trial.
Rajkumar SV; Frytak S; Rubin J; Camoriano JK; Fitch TR
Am J Clin Oncol; 1997 Oct; 20(5):500-4. PubMed ID: 9345336
[TBL] [Abstract][Full Text] [Related]
35. A phase I study of etoposide phosphate plus paclitaxel.
Brooks DJ; Alberts DS
Semin Oncol; 1996 Dec; 23(6 Suppl 13):30-3. PubMed ID: 8996573
[TBL] [Abstract][Full Text] [Related]
36. Daily oral etoposide in metastatic breast cancer.
Nesković-Konstantinović ZB; Bosnjak SM; Radulović SS; Mitrović LB
Anticancer Drugs; 1996 Jul; 7(5):543-7. PubMed ID: 8862722
[TBL] [Abstract][Full Text] [Related]
37. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial.
Schneider TC; Abdulrahman RM; Corssmit EP; Morreau H; Smit JW; Kapiteijn E
Eur J Endocrinol; 2012 Nov; 167(5):643-50. PubMed ID: 22918300
[TBL] [Abstract][Full Text] [Related]
38. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91-06.
Lee JS; Scott C; Komaki R; Fossella FV; Dundas GS; McDonald S; Byhardt RW; Curran WJ
J Clin Oncol; 1996 Apr; 14(4):1055-64. PubMed ID: 8648357
[TBL] [Abstract][Full Text] [Related]
39. Results of phase I-II trial of concomitant hyperfractionated radiation and oral etoposide (VP-16) in patients with unresectable squamous cell carcinoma of the head and neck.
Khafif A; Canfield VA; Syzek EJ; Medina JE
Am J Otolaryngol; 2003; 24(1):1-5. PubMed ID: 12579475
[TBL] [Abstract][Full Text] [Related]
40. A randomized phase I study of oral etoposide with or without granulocyte-macrophage colony-stimulating factor for the treatment of patients with advanced cancer.
Weiss GR; Shaffer DW; DeMoor C; Rinaldi DA; Rodriguez GI; Eckardt JR; Stephens C; Von Hoff DD
Anticancer Drugs; 1996 Jun; 7(4):402-9. PubMed ID: 8826608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
